Key result
ARBs linked to a ~46% lower risk of incident dementia versus non-ARBs.
Why the study?
Do angiotensin receptor blockers reduce the risk of dementia in high vascular-risk individuals?
Population
49,062 patients from the Taiwan National Health Insurance Research Database, described as high vascular-risk…
Comparison
Angiotensin receptor blockers (ARBs) vs Non-ARB-exposed patients (1:1 matched)
Design
Cohort
Follow-up
11-year follow-up period
Authors
Loading...
Does not support changing practice to favor ARBs for dementia prevention; leaves open whether RCTs confirm this association.
Cohort (n=49,062)
Yes
Do angiotensin receptor blockers reduce the risk of dementia in high vascular-risk individuals?
Effect estimate: HR 0.54 (95% CI 0.51-0.59)
Absolute Event Rate: 5.4% vs 8.9%
ARB use is associated with a significantly reduced risk of incident dementia, Alzheimer's disease, and vascular dementia in a dose-dependent manner among high vascular-risk individuals.
Chiu et al. (2014) conducted a cohort in Dementia (n=49,062). Angiotensin receptor blockers (ARBs) vs. Non-ARB exposure was evaluated on Incident cases of dementia (HR 0.54, 95% CI 0.51-0.59). Angiotensin receptor blockers were associated with a reduced risk of incident dementia compared to non-ARB exposure (HR 0.54; 95% CI 0.51-0.59) over an 11-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: